These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1350581)

  • 1. Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function.
    Dollfus S; Petit M; Menard JF; Lesieur P
    J Autism Dev Disord; 1992 Mar; 22(1):47-60. PubMed ID: 1350581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Platelet serotonin in infantile autism. Cross-over effects of a dopamine agonist and an antagonist].
    Dollfus S; Petit M; Launay JM; Callebert J; Boudou P; Dreux C; Ménard JF
    Encephale; 1992; 18(6):605-10. PubMed ID: 1364154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amisulpride versus amineptine and placebo for the treatment of dysthymia.
    Boyer P; Lecrubier Y; Stalla-Bourdillon A; Fleurot O
    Neuropsychobiology; 1999; 39(1):25-32. PubMed ID: 9892856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
    Wetzel H; Gründer G; Hillert A; Philipp M; Gattaz WF; Sauer H; Adler G; Schröder J; Rein W; Benkert O
    Psychopharmacology (Berl); 1998 Jun; 137(3):223-32. PubMed ID: 9682999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
    Freeman HL
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S11-7. PubMed ID: 9218163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of negative symptoms in schizophrenia with amisulpride.
    Boyer P; Lecrubier Y; Puech AJ; Dewailly J; Aubin F
    Br J Psychiatry; 1995 Jan; 166(1):68-72. PubMed ID: 7894879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report.
    Bliesener N; Yokusoglu H; Quednow BB; Klingmüller D; Kühn KU
    Pharmacopsychiatry; 2004 Jul; 37(4):189-91. PubMed ID: 15467977
    [No Abstract]   [Full Text] [Related]  

  • 9. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amisulpride: progress and outcomes.
    Lecrubier Y
    Curr Med Res Opin; 2002; 18 Suppl 3():s18-22. PubMed ID: 12418608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catecholamines in autistic disorder: effects of amisulpride and bromocriptine in a controlled crossover study.
    Dollfus S; Petit M; Garnier JP; Boudou P; Troupel S; Dreux C; Menard JF
    J Child Adolesc Psychopharmacol; 1993; 3(3):145-56. PubMed ID: 19630674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.
    Mortimer A; Martin S; Lôo H; Peuskens J;
    Int Clin Psychopharmacol; 2004 Mar; 19(2):63-9. PubMed ID: 15076013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators.
    Ravizza L
    J Psychopharmacol; 1999; 13(3):248-54. PubMed ID: 10512080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.
    Vanelle JM; Douki S
    Eur Psychiatry; 2006 Dec; 21(8):523-30. PubMed ID: 17113759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of dopamine research in schizophrenia.
    Pani L
    Curr Med Res Opin; 2002; 18 Suppl 3():s3-7. PubMed ID: 12418605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia.
    Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2001 Oct; 251(5):217-24. PubMed ID: 11829208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
    Leucht S; Pitschel-Walz G; Engel RR; Kissling W
    Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus on the use of substituted benzamides in psychiatric patients.
    Racagni G; Canonico PL; Ravizza L; Pani L; Amore M
    Neuropsychobiology; 2004; 50(2):134-43. PubMed ID: 15292667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
    Pélissolo A; Krebs MO; Olié JP
    Encephale; 1996; 22(3):215-9. PubMed ID: 8767050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on amisulpride in schizophrenia.
    Curran MP; Perry CM
    CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.